Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02101918 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

NIH

Sponsor class

Conditions

Multiple Endocrine Neoplasia Type 1
Pancreatic Neuroendocrine Carcinoma

Interventions

RADIATION: Computed Tomography Perfusion Imaging
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Ziv-Aflibercept

Sponsor

National Cancer Institute (NCI)